Daniel Joseph Oconnell Sells 12,619 Shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Stock

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) CEO Daniel Joseph Oconnell sold 12,619 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $1.59, for a total value of $20,064.21. Following the completion of the transaction, the chief executive officer now directly owns 667,488 shares in the company, valued at approximately $1,061,305.92. This represents a 1.86 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Daniel Joseph Oconnell also recently made the following trade(s):

• On Friday, January 3rd, Daniel Joseph Oconnell sold 47,778 shares of Acumen Pharmaceuticals stock. The stock was sold at an average price of $1.84, for a total value of $87,911.52.

Acumen Pharmaceuticals Stock Down 1.1 %

NASDAQ:ABOS opened at $1.73 on Friday. The company has a current ratio of 10.43, a quick ratio of 10.43 and a debt-to-equity ratio of 0.14. The company has a market cap of $103.94 million, a price-to-earnings ratio of -1.25 and a beta of 0.02. The stock has a fifty day simple moving average of $1.96 and a 200-day simple moving average of $2.46. Acumen Pharmaceuticals, Inc. has a twelve month low of $1.53 and a twelve month high of $5.09.

Acumen Pharmaceuticals (NASDAQ:ABOS) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.14). During the same period in the prior year, the firm earned ($0.24) EPS. Analysts anticipate that Acumen Pharmaceuticals, Inc. will post -1.56 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of ABOS. SG Americas Securities LLC acquired a new position in Acumen Pharmaceuticals during the 3rd quarter valued at about $44,000. American Century Companies Inc. boosted its holdings in Acumen Pharmaceuticals by 31.3% in the second quarter. American Century Companies Inc. now owns 45,444 shares of the company’s stock valued at $110,000 after purchasing an additional 10,840 shares during the last quarter. Rhumbline Advisers acquired a new stake in Acumen Pharmaceuticals during the second quarter worth about $127,000. Murchinson Ltd. purchased a new position in shares of Acumen Pharmaceuticals during the 2nd quarter valued at approximately $136,000. Finally, Barclays PLC raised its position in shares of Acumen Pharmaceuticals by 189.1% in the third quarter. Barclays PLC now owns 61,997 shares of the company’s stock worth $154,000 after acquiring an additional 40,551 shares during the period. Hedge funds and other institutional investors own 71.01% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and set a $15.00 target price on shares of Acumen Pharmaceuticals in a research report on Wednesday, November 13th.

About Acumen Pharmaceuticals

Acumen Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers.